POET Technologies ($POET) Stock Hub 2026: Q2 Results, $796 Million in Cash, the Lumilens Order and What Is Actually Funded
POET makes an optical interposer that integrates lasers and optics onto a single platform for data centre transceivers. The second quarter print of August 13, 2026 confirms the balance sheet at $796.3 million and revenue at $569,925, and leaves the same question standing: one funded purchase order, one framework described as capable of scaling far beyond it, and a warrant that was granted to secure both.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
At a glance
Revenue rose 13% on the first quarter and 112% on the second quarter of 2025, the sixth consecutive sequential increase, and the net loss narrowed from $12.34 million to $11.34 million, or $0.07 per share. Nothing has yet been recognised against the $50 million Lumilens purchase order: the $30,142,069 attached to that relationship sits on the balance sheet as deferred customer consideration, the accounting value of the first warrant tranche, and it will be amortised only once product revenue from that customer begins. The next dated marker is management’s stated intention to make further announcements in September 2026, which is a company statement of intent and not a scheduled event.
Every count is stated by the company at August 13, 2026 in the outstanding share data section of the management discussion, which also gives 173,035,169 shares at June 30. Warrants and options are unchanged between the two dates; the shares and the restricted stock units are not. Adding all four gives 261,414,953 shares on full exercise, 51% above the count in issue. The warrants are struck between $1.09 and $26.25 and carry $435,942,629 in the warrant reserve. They fall into three groups: 19,047,620 at $26.25 from the May 2026 unit offering, expiring May 18, 2029; 22,921,408 at $8.25 granted to Lumilens, of which 20,629,268 vest only as payment milestones are met; and 36,765,940 left from earlier rounds, carried at a weighted average of $3.77 at the last date the company disclosed one.
01 The second quarter 2026 print, reported August 13, 2026
POET filed its interim statements and management discussion on August 13, 2026, one day before the regulatory deadline. The documents reached SEDAR+ and were furnished to the SEC on a Form 6-K accepted at 09:13:55 Eastern time, with a results press release issued at 07:01 Eastern. Revenue for the quarter was $569,925, against $503,389 in the first quarter of 2026 and $268,469 in the second quarter of 2025: up 13% sequentially and 112% year on year, which the company describes as its sixth consecutive quarter of sequential growth. The net loss was $11,338,060, or $0.07 per share, narrowing from $12,344,086 and $0.08 in the first quarter and from $17,263,375 and $0.21 a year earlier.
| Line, US dollars | Q2 2026 | Q1 2026 | Q2 2025 |
|---|---|---|---|
| Revenue | $569,925 | $503,389 | $268,469 |
| Research and development | $(5,784,056) | $(4,499,556) | $(3,150,044) |
| Wages and benefits | $(2,778,119) | $(4,046,941) | $(1,042,380) |
| Stock-based compensation | $(3,816,906) | $(3,486,766) | $(1,165,482) |
| Finance advisory fees | $(6,172,500) | $(3,252,500) | $(1,302,464) |
| Derivative liability adjustment | $5,531,784 | $1,602,298 | $(7,559,991) |
| Other income, including interest | $4,299,496 | $3,970,291 | $533,308 |
| Net loss | $(11,338,060) | $(12,344,086) | $(17,263,375) |
| Loss per share, basic | $(0.07) | $(0.08) | $(0.21) |
Two lines inside that table carry more weight than the loss itself. Finance advisory fees of $6,172,500 are the largest single cost of the quarter, larger than research and development, and they are the price of the May financing: the offering was non-brokered, which does not mean it was free. Other income of $4,299,496 is almost entirely interest, and it is now running at a level that covers a meaningful share of the cash operating cost: the treasury has become a profit centre in its own right while the product is still pre-revenue at scale.
The derivative liability adjustment of $5,531,784 is a non-cash gain and does not reflect operations. It is the quarterly remeasurement of warrants that are exercisable into a variable number of shares, and the company states the mechanism explicitly in the notes.
The four questions this print was going to answer, and what it answered. Cash and short-term investments at June 30, 2026 came in at $796,341,903, so the roughly $830 million of gross proceeds raised since May 2025 survives contact with a filed balance sheet net of what has been spent and lent. Nothing has been recognised against the Lumilens order: revenue is still described as non-recurring engineering and product revenue combined, and the $30,142,069 tied to that customer sits as deferred customer consideration, to be amortised only when product revenue from the customer starts. The share count on the cover is 173,035,169, against 172,595,406 at the May financing, so the quarter added 439,763 shares, almost all of them from warrant exercises. The derivative warrant liability moved from $2,584,759 at March 31 to $22,020,827 at June 30, and the notes give the reason: the 2,292,140 vested Lumilens warrants have a cashless exercise feature, which makes the number of shares issuable variable and forces them back into liabilities at a fair value first recorded at $30,142,069.
The reporting rhythm, now with the second quarter filled in
POET is a reporting issuer in Canada and, because its shares are listed on Nasdaq, it is not a venture issuer under National Instrument 51-102. Non-venture issuers must file an interim financial report within 45 days of the end of the interim period. The pattern is tight against that deadline in every recent quarter.
| Reporting period | Filed or reported | Timing versus deadline |
|---|---|---|
| Q2 2026 | Filed Aug 13, 2026 | Deadline was Aug 14. One day early. |
| Q1 2026 | Filed May 14, 2026 | Deadline was May 15. Results release the same day. |
| Q3 2025 | Filed Nov 14, 2025 | Deadline was Nov 14. Filed on the last permitted day. |
| Q2 2025 | Filed Aug 12, 2025 | Deadline was Aug 14. Two days early. |
| Q4 and full year 2025 | Reported Apr 1, 2026 | Form 20-F filed March 31, 2026. |
On that rhythm the third quarter of 2026 ends on September 30 and the interim report is due by November 14, 2026. No date has been announced for it, and the company has not committed to one.
There is no conference call. This is a genuine difference from most Nasdaq-listed peers and it is useful to know in advance rather than searching for a dial-in that does not exist. POET does not host a quarterly earnings call, does not publish a webcast link with its results and does not issue prepared remarks: the August 13 release follows the same pattern as every quarterly release since the second quarter of 2025. Management commentary arrives as quoted paragraphs inside the results press release, and the one live event of the year is the annual general meeting, at which the chief executive gives a business update with a question and answer session. The 2026 edition was held virtually on June 26 and the recording and slides were posted afterwards.
Direct links: the August 13, 2026 Form 6-K · POET filings on EDGAR · SEDAR+ · POET investor relations.
02 Executive summary
POET Technologies designs optical engines and light sources for artificial intelligence networks and hyperscale data centers, built on a patented platform it calls the POET Optical Interposer. The technology has been validated by partners, by industry awards and by paying customers ordering samples and pre-production volumes. What it has not yet done is produce revenue at any material scale. Cumulative revenue for the three full years 2023, 2024 and 2025 plus the first half of 2026 is $2,655,383. Over the same period the accumulated deficit reached $320,776,480 at June 30, 2026.
Against that, the balance sheet has been transformed. Six equity financings between May 2025 and May 2026 raised $830 million in gross proceeds, a figure the chief executive repeated at the June 2026 annual meeting and the company restated in a July 14, 2026 note on its own website. The largest of them, $400 million, closed on May 18, 2026 with a single institutional buyer, MMCAP International Inc. SPC, at $21.00 per unit, a premium to the prior close, with a three-year warrant struck at $26.25.
The second quarter print of August 13, 2026 put a filed number on both halves of that sentence: $796,341,903 of cash and short-term investments, and $569,925 of quarterly revenue. The company now has more cash than most of its listed peers in optical components and almost no revenue to defend it. That combination is the whole debate. It is also why the two most important sentences in POET’s disclosure record over the last twelve months are not about technology at all. The first is from April 27, 2026: Marvell, having acquired Celestial AI, cancelled every purchase order Celestial had placed with POET, the orders POET had been citing publicly since April 2023. The second is from May 14, 2026: Lumilens placed a $50 million initial purchase order, and the same release states that fulfilment “is subject to the successful development and ultimate qualification of the modules, as well as the successful scaling of manufacturing capability.”
Three categories need to be kept apart when reading anything about this company, because commentary routinely merges them: revenue actually recognized on a filed income statement, purchase orders that are signed but conditional on qualification and manufacturing scale-up, and joint development agreements, collaborations and memoranda that carry no order at all. POET has entries in all three columns. The third column is by far the longest, and it is the one most often described as if it belonged in the first.
03 Market Data And Peer Comparison
Price, performance, float, ownership, short interest, average volume and the consensus target below are from Finviz, pulled during the session of Thursday, August 13, 2026 at 10:54 Eastern time, the day the second quarter results were released. Intraday values move; the reference time is stated so the reading can be reproduced. Company financial figures come from SEC filings and company releases, each carrying its own reference date.
| Metric | $POET |
|---|---|
| Price | $9.27, up 4.51% on the session |
| Market capitalisation | ~$1.60B |
| Shares outstanding | 173,035,169 on the filed balance sheet at June 30, 2026 |
| Float | 90.61M, Finviz |
| Insider / institutional ownership | 0.13% / 78.87% |
| Short interest | 28.49% of float |
| Average volume / volume by 10:54 | 27.18M / 8.42M, relative volume 1.22 |
| Volatility, week / month | 8.12% / 8.29% |
| Performance: week / month / quarter | 8.68% / 12.09% / -35.49% |
| Performance: half year / year to date / year | 59.01% / 46.45% / 77.59% |
| Sell-side consensus target | $20.25, Finviz aggregate, August 13, 2026 |
Finviz reports shares outstanding of 152.89 million, which is the figure from the March 31, 2026 balance sheet and predates the May unit offering. The count used throughout this page is the one on the cover of the June 30, 2026 interim statements, 173,035,169. The market capitalisation shown by the same source, roughly $1.60 billion at $9.27, is consistent with the larger count rather than the smaller one.
Peer comparison, Finviz reading of August 13, 2026 at 10:54 Eastern
| Ticker | Price | Market cap | Short float | Year to date | One year |
|---|---|---|---|---|---|
| $POET | $9.27 | $1.60B | 28.49% | 46.45% | 77.59% |
| $LPTH | $13.53 | $897.9M | 16.67% | 25.28% | 262.73% |
| $AI | $9.83 | $1.53B | 33.84% | -27.09% | -47.16% |
| $BBAI | $3.26 | $1.56B | 31.12% | -39.58% | -43.85% |
| $SOUN | $7.36 | $3.21B | 41.55% | -26.21% | -55.41% |
| $IREN | $46.40 | $16.56B | 31.88% | 22.86% | 161.73% |
| $ONDS | $9.17 | $5.23B | 44.60% | -6.05% | 160.51% |
| $RKLB | $82.84 | $49.57B | 7.78% | 18.75% | 92.65% |
The twelve-month range is the context for everything else: an intraday high of $20.81 on May 14, 2026, the day the Lumilens agreement was announced and the day before a $400 million offering was disclosed, against an intraday low of $3.87 on November 21, 2025. A range of more than five to one in twelve months is a statement about how thinly the outcome is currently known. The quarter-to-date performance of -35.49% is measured from inside that May spike, not from a settled level.
Short interest at 28.49% of float is down from 30.11% at the August 7 reading used in the previous version of this page, and remains among the highest in the peer set. Of the eight names in the table, five carry a short float above 28%.
Analyst coverage is reported here in a deliberately narrow form. The consensus target above is a Finviz aggregate of third-party estimates. Individual houses, ratings and note dates were not verified for this update, so no coverage table is presented. A consensus figure without named notes behind it is a market-data point, not research, and it is neither a company figure nor a Merlintrader forecast.
04 Verified developments, most recent first
August 13, 2026 · Second quarter results, and three items disclosed for the first time
Revenue of $569,925, a net loss of $11,338,060 or $0.07 per share, and cash plus short-term investments of $796,341,903 at June 30, 2026. Alongside the numbers the release carries three business items that had not been disclosed before, all of them after the quarter end: a new purchase order of $2.4 million from an existing customer, an agreement with a Tier 1 laser company to develop an external light source engine, and an exclusive arrangement with a supplier for a component that raises the output power of the Blazar hybrid laser. None of the three names a counterparty and none carries a delivery date. The same release ends the redomiciliation question: the board determined that at the present time it is not in the best interests of the company to move forward with redomiciling to the United States. Management states it expects to begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026 and to make further announcements in September.
August 11, 2026 · Restricted stock units granted to officers
The board approved a grant of 2,453,271 restricted stock units to officers, sized using the August 10 Nasdaq close of $8.56 and vesting one third on each of the first three anniversaries. The management discussion filed two days later reports restricted stock units outstanding of 3,885,953 at June 30, 2026 and 4,252,504 at August 13, 2026. Those two disclosures do not reconcile arithmetically with the full grant, and the company does not explain the difference; the figures are reported here as filed, from the two documents that state them.
August 3, 2026 · Board changes
POET appointed Dr. Bardia Pezeshki and Jean F. Rankin to the board with effect from August 1, 2026, and accepted the resignation for personal reasons of Jean-Louis Malinge, a director since 2017. Dr. Pezeshki founded and led Avicena Tech, Kaiam Corporation and Santur Corporation and holds a doctorate in electrical engineering from Stanford. Ms. Rankin is a director of InterDigital and a former general counsel of LSI Corporation and Agere Systems. Each received 21,460 restricted stock units vesting on June 26, 2027.
July 14 and July 29, 2026 · Company disclosures on its own website
Two notes published by POET set out targets that do not appear in any filing: more than 30,000 optical engine shipments across 2026, samples of the joint 1.6T 2xDR4 module with Lessengers targeted for the third quarter of 2026, and a restatement that the company held more than $830 million in cash and short-term investments as of June 2026 with little debt. The Lessengers sample target had been the second quarter of 2026 in the March announcement, so it has moved by one quarter.
June 30, 2026 · Annual meeting results and business update
All resolutions in the circular passed, with no director receiving less than 94.35% of votes cast and Davidson & Company LLP reappointed as auditor with 97%. The company disclosed 172,590,000 shares issued and outstanding at the time of the meeting. The chief executive stated that the production ramp remains on schedule to begin in the second half of 2026, that capacity is intended to reach up to one million units per month by the end of 2027, that roughly $50 million of capital equipment purchases are planned for the second half of 2026, that there are more than ten active customer engagements which combined are expected to exceed $100 million in future annual revenue, and that headcount of 115 would grow by about 50 within a few months. The voting report lists only the election of directors and the appointment of the auditor; no resolution on the U.S. redomiciliation announced in April is recorded as having been put to shareholders.
May 18, 2026 · $400 million closes
POET issued 19,047,620 common shares and a warrant over 19,047,620 shares to a single institutional investor at a combined price of $21.00, raising gross proceeds of $400,000,020. The warrant is exercisable for three years at $26.25, a 25% premium. A Schedule 13G/A filed on May 20 identifies the buyer as MMCAP International Inc. SPC, managed by MM Asset Management Inc. of Ontario, reporting 19,047,620 shares and 11.0% of the class. Management said capacity is being expanded roughly ten-fold in both wafer production and optical engine assembly, that headcount had passed 115, that the Singapore footprint had grown nearly three-fold and that there is 20,000 square feet of assembly space in Malaysia.
May 14 and 15, 2026 · Lumilens agreement and first quarter results
POET and Lumilens Inc. entered a supply agreement framing a joint development program around an Electrical-Optical Interposer. Lumilens placed an initial purchase order valued at $50 million for EOI-based engines, described as the first phase of a relationship that could scale beyond $500 million cumulatively over five years. POET granted Lumilens a warrant over up to 22,921,408 shares at $8.25, exercisable over nine years, of which 2,292,140 vested immediately and the remainder vests in tranches against cumulative payments toward the $500 million. Engineering samples are expected in late 2026 with a production ramp aligned to hyperscaler deployments in 2027. First quarter results, released the same week, showed revenue of $503,389 and a net loss of $12.34 million.
May 12, 2026 · Chief operating officer appointed
Dr. Sandeep Kumar joined as chief operating officer effective May 11, 2026, from Silicon Labs where he was senior vice president of worldwide operations across more than eighteen years, with earlier roles at Agere Systems, Lucent Technologies and AT&T Bell Labs.
April 27, 2026 · Marvell cancels the Celestial AI orders
POET announced the cancellation of all purchase orders received from Celestial AI, including the initial production units first disclosed in an April 2023 press release. Marvell Semiconductor, which had acquired Celestial AI, gave written notice on April 23, 2026, stating as the basis that POET had disclosed information about the purchase order and shipping in contravention of its confidentiality obligations. The shares closed at $15.10 on April 24 and at $7.95 on April 27, a fall of 47.4% in one session.
April 14, 2026 · PFIC status and the plan to redomicile
POET confirmed it will make available the information U.S. shareholders need to make a qualified electing fund election in respect of its status as a passive foreign investment company for the year ended December 31, 2025, and said it does not expect to qualify as a PFIC for 2026. The board declared its intention to move the headquarters to, and redomicile the company in, the United States so that it would no longer be a foreign corporation.
March 16 and 17, 2026 · LITEON and Lessengers
A strategic collaboration with LITEON Technology to co-develop optical communication modules on the POET Optical Interposer, and an expanded partnership with Lessengers to jointly develop a 1.6T 2xDR4 optical transceiver module combining POET optical engines with Lessengers’ Direct Optical Wiring technology. Neither announcement carried a purchase order or a disclosed value.
January 23, 2026 · $150 million registered direct
20,689,656 common shares at $7.25 raised gross proceeds of $150,000,006 under the automatic shelf registration statement that became effective on January 22, 2026.
December 31, 2025 · Super Photonics Xiamen bought in and closed
POET acquired Sanan’s shares in the Super Photonics Xiamen joint venture for $6,500,000, taking ownership to 100%. The Form 20-F filed in March 2026 states that the transfer of production equipment out of China to the Malaysian partners is complete, that the joint venture has been dissolved and the operation permanently closed, and that the final wind-up awaits an audit and filings with the Chinese authorities.
November 11 and 14, 2025 · Quantum Computing Inc. collaboration and Q3 results
POET and Quantum Computing Inc. ($QUBT) agreed to co-develop 400G-per-lane thin-film lithium niobate modulator-based 3.2 Tbps optical engines for co-packaged optics, with POET funding the modulator development, targeted for completion in the second half of 2026. Third quarter 2025 revenue was $298,434.
October 2025 · $75 million, $150 million and the $5 million order
Three items in one month. On October 7 a non-brokered private placement of 13,636,364 units raised CA$104,625,002, or $75,000,000. On October 22 POET announced a production order valued at more than $5 million for POET Infinity 800G optical engines from an unnamed “leading systems integrator”, for shipment in the second half of 2026. On October 28 a brokered registered direct offering of 20,689,655 shares raised $150,000,000.
August 25 to 29, 2025 · TSXV delisting and NTT partnership
POET announced it would proceed with the voluntary delisting of its shares from the TSX Venture Exchange, effective on or about the close on August 27, 2025, leaving Nasdaq as the sole listing. Four days later it announced a partnership with NTT Innovative Devices to develop a 100G bidirectional optical engine for mobile front-haul networks.
05 The numbers in five charts
Every bar below is drawn from a figure published by POET in an interim or annual financial statement or in a results press release. Bar widths are the stated value as a percentage of the largest bar in the same chart.
Revenue by quarter, Q1 2025 to Q2 2026 (US dollars)
Source: the five-quarter summary in POET’s second quarter 2026 results release of August 13, 2026, and the eight-quarter table in the accompanying management discussion. The trend is up in every quarter and the scale is the point: the largest bar is $569,925. The company describes this line as non-recurring engineering and product revenue combined, and does not split the two. The 112% year-on-year increase is measured against $268,469.
Total operating costs by quarter, Q1 2025 to Q2 2026 (US dollars)
Calculated by adding the seven cost lines POET publishes in its own quarterly table: research and development, depreciation and amortization, professional fees, wages and benefits, stock-based compensation, general expenses and rent, and finance advisory fees. Cost has more than doubled in five quarters. In the second quarter of 2026 the largest single line is not research and development but finance advisory fees of $6,172,500, the cost of raising the $400 million, against $3,252,500 in the first quarter. Research and development of $5,784,056 is the second line and the one that grew for product reasons, up 84% on the $3,150,044 of a year earlier, which the company attributes to engineering headcount, customer-specific programmes and manufacturing readiness. Stock-based compensation of $3,816,906 is non-cash.
Cash and short-term investments at each reporting date (US dollars)
All four bars are balance sheet figures: cash and cash equivalents plus short-term investments, from the audited 2025 annual statements, the first quarter 2026 statements and the June 30, 2026 interim statements. At June 30 the split is $432,531,904 of cash and cash equivalents and $363,809,999 of short-term investments, the latter held as guaranteed investment certificates with Canadian banks. Within the cash line, $404,211,716 sits in current accounts and $28,320,188 in term deposits and high-interest savings earning between 2.25% and 3.24%.
The filed figure of $796.3 million comes in below the “more than $830 million” the company described at the June annual meeting and repeated on its website on July 14, 2026, and the gap is accounted for rather than unexplained. Between March 31 and June 30 POET received $400,000,020 of gross proceeds, spent $12.2 million on operations in the quarter, lent $30 million to an unnamed borrower at 6%, paid $2,955,150 for a 4.99% stake in Lessengers and incurred the finance advisory fees on the raise. Those uses are disclosed individually in the interim statements.
Common shares issued and outstanding (millions)
Sources: the share capital note in the 2025 annual statements and the first quarter 2026 statements for the first three bars. The May 18, 2026 figure of 172,595,406 is taken from the prospectus supplement filed that day and independently repeated in the Schedule 13G filed by Citadel Securities on July 8, 2026. The company stated 172,590,000 shares at the June 26 annual meeting. The count has risen 126% since the start of 2025.
Gross proceeds by financing round, May 2025 to May 2026 (US dollars)
Sources: the share capital note in the first quarter 2026 financial statements for the first five rounds, and the closing press release of May 18, 2026 for the sixth. The first three were unit placements priced in Canadian dollars with warrants attached; the October 2025 and January 2026 rounds were registered direct offerings of common shares at $7.25; the last was a registered direct offering of shares with a warrant at a combined $21.00. The six rounds sum to $830.0 million, which is the figure management cites.
Total assets of $881,805,309, by carrying value
- Cash and cash equivalents$432.53M49.1%
- Short-term investments$363.81M41.3%
- Loan receivable$30.64M3.5%
- Deferred customer consideration$30.14M3.4%
- Property and equipment$15.85M1.8%
- Everything else$8.83M1%
Ninety per cent of the balance sheet is cash and short-term investments. Property and equipment, the line that would carry a manufacturing ramp, is 1.8% of assets.
Source: Condensed interim consolidated statement of financial position, Form 6-K filed August 13, 2026.
Millions of shares. The warrant is potential issuance, not shares already outstanding.
- Shares outstandingAt May 18, 2026, per the prospectus supplement. Finviz reported a float of 90.48M on August 7.172.60M88.3%
- Lumilens warrant, if fully exercisedA nine-year warrant over up to 22,921,408 shares at $8.25, of which 2,292,140 were immediately exercisable. Granted as part of the May 14, 2026 agreement.22.92M11.7%
Against the 172,595,406 shares reported after the May financing, full exercise would add about 13.3% to the current share count, or 11.7% of the enlarged total. The strike of $8.25 sits close to the August 7 close of $8.91, so the warrant is currently near the money. This is a disclosed and ordinary way to secure an anchor customer; it is also the reason the $50 million order should not be read as free.
Source: Company announcement of May 14, 2026 and prospectus supplement of May 18, 2026; Finviz float at August 7, 2026.
06 What the POET Optical Interposer actually is
An optical transceiver converts electrical signals into light and back again. Building one has traditionally meant placing lasers, modulators, photodiodes, multiplexers, drivers and amplifiers next to one another and aligning them to fiber one at a time, with a machine holding each part while light is measured through it. That step, called active alignment, is the single largest source of cost, yield loss and throughput limitation in optical module assembly. It is manual, it is slow, and it does not get cheaper with volume in the way semiconductor processing does.
The POET Optical Interposer is a silicon substrate on which those components are assembled at wafer level using chip-scale processes, with the optical waveguides and coupling structures already patterned into the substrate. Because the optical paths are defined lithographically rather than by physically nudging parts into position, assembly can be passive. POET’s own description of the resulting advantage is consistent across filings and releases: lower cost, lower power, smaller size and scalability to high production volumes, with wire bonds eliminated, the multiplexer and demultiplexer monolithically integrated, and a materially reduced bill of materials.
The product families
- POET Infinity is the 800G line. It is built from 400G optical engines that can be daisy-chained, and it is the product behind the October 2025 production order: 2xFR4 and 2xDR4 400G transmit engines and 800G 2xFR4 and DR8 receive engines, with integrated electro-absorption modulated lasers, drivers and multiplexers on the transmit side and high-speed photodiodes, transimpedance amplifiers and demultiplexers on the receive side.
- POET Teralight extends the same platform to 1.6 Tbps, with transmit and receive chipsets sampled during 2025. It won the Product Innovation Award at the 12th ICCSZ Infostone Awards and, according to the company, an elite score of 4.5 in the 2026 Lightwave Innovation Reviews.
- POET Blazar is the hybrid laser at the center of the external light source strategy, with POET Starlight as the external light source product line. At the June 2026 annual meeting management said Blazar remains on schedule for deployment at scale in 2028, which is the furthest-out date the company has publicly attached to a product.
Why co-packaged optics matters here
Today’s artificial intelligence clusters connect switches and accelerators using pluggable transceivers that sit at the faceplate. As bandwidth per port rises from 400G to 800G to 1.6T, the electrical distance between the switch silicon and the faceplate becomes a power and signal-integrity problem. Co-packaged optics moves the optical engine onto the same substrate as the switch or accelerator package, which shortens that electrical path dramatically. It also removes the laser from the hot package, which is why an external light source becomes a separate product category rather than a component inside the module.
POET’s argument is that a platform designed for wafer-level integration is agnostic to which architecture wins, because the same interposer can be built into a pluggable module today and sit beside a switch ASIC tomorrow. The claim that a customer can qualify once and migrate across speed tiers without a ground-up redesign is a real commercial argument in a market where hyperscale qualification cycles can run a year or more. It is also, as of August 2026, a claim that has not yet been demonstrated by a customer taking a POET-based product from qualification through to volume deployment.
07 Partners, collaborations and the Xiamen joint venture
POET runs what it calls a fab-light strategy: it designs, and partners manufacture. The list of named counterparties is unusually long for a company of this size, and each entry sits at a different point on the spectrum from signed commercial commitment to exploratory development.
| Counterparty | Announced | What was actually agreed |
|---|---|---|
| Lumilens Inc. | May 14, 2026 | Supply agreement plus joint development on the Electrical-Optical Interposer. Initial purchase order of $50 million; framework described as capable of scaling beyond $500 million over five years. POET granted a nine-year warrant over up to 22,921,408 shares at $8.25, 2,292,140 immediately exercisable. Samples expected late 2026, ramp aligned to 2027 hyperscaler deployments. Fulfillment stated to be subject to development, qualification and manufacturing scale-up. |
| Unnamed “leading systems integrator” | Oct 22, 2025 | Production order valued at more than $5 million for POET Infinity 800G engines, shipment targeted for the second half of 2026. The customer has never been named. |
| Globetronics Manufacturing (GMSB), Malaysia | Manufacturing agreement | Cleanroom of about 10,000 square feet with all POET wafer-level processing equipment installed, described in the 20-F as having capacity for one million optical engines annually. |
| NationGate Solution (M), Malaysia | June 24, 2025 | Manufacturing agreement for a comparable cleanroom dedicated to light source production. Equipment installation was still under way at the date of the 20-F. |
| LITEON Technology | Mar 16, 2026 | Strategic collaboration to co-develop optical communication modules. No purchase order, no disclosed value, no dated milestone. |
| Lessengers | Mar 17, 2026 | Joint development of a 1.6T 2xDR4 transceiver combining POET engines with Lessengers’ Direct Optical Wiring. Samples were targeted for Q2 2026 in the announcement and are described as targeted for Q3 2026 in the company’s July 14, 2026 note. No order value. |
| Quantum Computing Inc. ($QUBT) | Nov 11, 2025 | Co-development of 400G-per-lane thin-film lithium niobate modulator-based 3.2 Tbps engines for co-packaged optics. POET funds the modulator development, targeted for completion in the second half of 2026. This is a cash outflow for POET, not an order. |
| Sivers Semiconductors ($SIVE.ST) | Sep 29, 2025 | Collaboration on external light source modules combining Sivers’ high-power distributed feedback lasers with the POET interposer. Development stage. |
| Semtech ($SMTC) | Sep 30, 2025 | 1.6T optical receivers integrating Semtech FiberEdge components on the POET platform. Product launch announcement, no order disclosed. |
| NTT Innovative Devices | Aug 29, 2025 | Development of a 100G bidirectional optical engine for mobile front-haul. A different end market from the AI data center story. |
| Celestial AI, then Marvell ($MRVL) | Cancelled Apr 23, 2026 | All purchase orders received from Celestial AI, including the initial production units publicised from April 2023, were cancelled by written notice from Marvell after it acquired Celestial AI. Marvell cited disclosure of purchase order and shipping information in contravention of confidentiality obligations. |
| Xiamen Sanan Integrated Circuit | JV formed 2021, closed 2025 | Super Photonics Xiamen was a joint venture formed in March 2021. POET acquired 24.8% in 2024, recording a $6.85 million loss on the acquisition, and bought Sanan’s remaining shares on December 31, 2025 for $6,500,000. The 20-F states production equipment has been transferred to Malaysia, the joint venture is dissolved, the operation is permanently closed and the entity is being wound up. |
Why the Xiamen exit matters. The joint venture was for several years described as POET’s route to volume manufacturing. The 20-F gives the reason in the company’s own words: it determined it could not achieve full operational control of the Xiamen operation within any joint venture structure, and it wanted to mitigate geopolitical risk in China. Manufacturing capacity therefore now depends on two Malaysian contract partners rather than on an entity POET part-owned.
08 Funded order, conditional order, or announcement: the distinction that decides this stock
POET has issued a large number of announcements naming large companies. Very few of them carry a number, and the ones that do carry conditions. Sorting them properly is the single most useful analytical act a reader can perform on this company, and the April 2026 cancellation is the reason.
What has actually converted into revenue
Revenue recognized on filed income statements since the start of 2023 totals $2,085,458: $465,777 in 2023, $41,427 in 2024, $1,074,865 in 2025 and $503,389 in the first quarter of 2026. All of the 2025 revenue was recorded in the Asia segment. The company describes the line as non-recurring engineering and product revenue combined and does not disclose the split, the number of customers or any customer concentration percentage. The contract liability note shows customer deposits of $230,000 taken in the first quarter of 2026 and $503,389 of revenue recognized in the same period, with an accounts receivable balance of $290,368 at March 31, 2026 against nil at December 31, 2025.
What is signed but conditional
- Lumilens, $50 million. The announcement is explicit: “Fulfilment of the purchase orders and associated revenues is subject to the successful development and ultimate qualification of the modules, as well as the successful scaling of manufacturing capability.” Engineering samples are expected in late 2026. A purchase order that depends on a module that does not yet exist passing a qualification that has not yet started is a commitment to buy something conditional, not a backlog figure.
- The unnamed systems integrator, more than $5 million. Announced October 22, 2025 for shipment in the second half of 2026. The customer is not identified and no update on shipment status has been published since.
What carries no order at all
LITEON, Lessengers, Quantum Computing Inc., Sivers, Semtech and NTT Innovative Devices are development collaborations. Two of them require POET to spend money rather than receive it: the QCi agreement states that POET funds the 400G-per-lane modulator development. Collaborations of this kind are how photonics products get built and their existence is a legitimate signal that credible counterparties take the platform seriously. They are not orders and none of them has a disclosed value.
The aggregate management figure, and how to read it
At the June 2026 annual meeting management said POET has more than ten active customer engagements which combined are expected to exceed $100 million in future annual revenue. That number is a management expectation about engagements, not a contracted backlog, and POET does not publish a backlog figure in the way an aerospace or defense supplier does. It sits alongside a stated target of more than 30,000 optical engine shipments across 2026 and a capacity ambition of up to one million units per month by the end of 2027. All three are forward-looking statements made outside a financial statement.
The lesson from Marvell. The Celestial AI orders were referenced by POET from April 2023 onward and were, for three years, the most frequently cited commercial validation of the platform. They were cancelled in a single letter, for a reason unrelated to product performance, and the shares fell 47.4% in one session. Any purchase order held by a customer that can be acquired, or that can invoke a confidentiality clause, is revocable until the product ships and the cash arrives.
Disclosed values in US$ millions.
The framework is described as capable of scaling beyond $500 million over five years. Fulfilment is stated to be subject to development, qualification and manufacturing scale-up. It is a description of potential, not an order.
Announced May 14, 2026 alongside a joint development agreement on the Electrical-Optical Interposer. Samples expected late 2026, ramp aligned to 2027 hyperscaler deployments.
Announced October 22, 2025 for POET Infinity 800G engines, shipment targeted for the second half of 2026. The customer has never been named.
Several other relationships carry no order and no value at all: a strategic collaboration with LITEON announced March 16, 2026 with no purchase order and no dated milestone, and a joint development with Lessengers announced March 17, 2026 whose sample target moved from the second quarter of 2026 to the third. Manufacturing agreements with Globetronics and NationGate in Malaysia provide capacity rather than demand.
Source: Company announcements of October 22, 2025 and May 14, 2026.
09 Financial position after the second quarter print
| Line, US dollars | FY2023 | FY2024 | FY2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue | $465,777 | $41,427 | $1,074,865 | $503,389 | $569,925 |
| Research and development | $10,077,930 | $11,334,641 | $18,084,303 | $4,499,556 | $5,784,056 |
| Finance advisory fees | see annual report | see annual report | $8,227,774 | $3,252,500 | $6,172,500 |
| Total operating expenses | $20,873,085 | $30,106,062 | $43,166,260 | $18,373,547 | $20,760,396 |
| Fair value movement on derivative warrant liability | $(24,865) | $(20,631,082) | $(25,280,833) | $1,602,298 gain | $5,531,784 gain |
| Other income, including interest | see annual report | see annual report | $4,531,201 | $3,970,291 | $4,299,496 |
| Net loss | $(20,267,365) | $(56,695,823) | $(62,963,213) | $(12,344,086) | $(11,338,060) |
| Loss per share, basic | $(0.51) | $(0.94) | $(0.68) | $(0.08) | $(0.07) |
| Cash used in operating activities | $(15,407,462) | $(23,291,311) | $(31,086,630) | $(8,800,000) approx | $(12,200,000) approx |
| Cash and short-term investments at period end | not comparable | $37,143,759 | $313,398,303 | $429,136,442 | $796,341,903 |
| Total assets at period end | $8,777,417 | $69,652,449 | $328,572,438 | $461,771,861 | $881,805,309 |
| Total liabilities at period end | $3,846,001 | $48,963,562 | $144,783,166 | $13,128,261 | $34,297,893 |
| Working capital at period end | not stated | not stated | $170,708,559 | not stated | $766,794,625 |
| Accumulated deficit | $(214,291,025) | $(270,986,848) | $(297,094,334) | $(309,438,420) | $(320,776,480) |
The annual columns come from the audited statements and the selected annual information table, where the line is total operating expenses. The two quarterly columns are the sum of the seven cost lines POET publishes in its own quarterly summary. The two bases are close but not identical.
Two features of this table need explanation. First, the collapse in total liabilities between December 2025 and March 2026, from $144.78 million to $13.13 million, is not a debt repayment. It is the derivative warrant liability falling from $135,631,585 to $2,584,759 because $131,444,528 of warrant fair value was reclassified out of liabilities and into the equity warrant reserve. That reclassification followed the change of functional currency to United States dollars on October 1, 2025, which removed the foreign-currency feature that had forced warrants issued in Canadian dollars to be carried as liabilities and remeasured every quarter. The same mechanism explains the $30.7 million non-cash loss in the fourth quarter of 2025 and the $15.4 million non-cash gain in the first quarter of 2025: both were fair-value swings on that liability, not operating events.
Liabilities then move the other way between March and June, from $13.13 million to $34.30 million, and again the cause is not borrowing. The derivative warrant liability rises from $2,584,759 to $22,020,827 because the 2,292,140 vested Lumilens warrants carry a cashless exercise feature: the number of shares issuable varies with the share price at exercise, which forces them into liabilities at a fair value first recorded at $30,142,069 and remeasured every quarter thereafter.
Second, the only real debt is $5,800,000 of convertible debt carried as a current liability at December 31, 2025, March 31, 2026 and June 30, 2026, reduced from $6,500,000 during 2025 by a $700,000 repayment. It is payable over four years and the holder may convert any unpaid amount at its discretion, which is why it sits in current liabilities. Lease liabilities are $1,997,859 in total. Against $796.3 million of cash and investments, the balance sheet carries effectively no leverage.
Two assets on the June 30 balance sheet are new and neither is operating. A loan receivable of $30,644,384 records three advances of $10 million, $5 million and $15 million made on January 7, January 21 and April 23, 2026 to a borrower the company does not name, for general working capital, at 6% compounding daily and 8% on default, repayable on the earlier of a liquidity event and five years, with a right for POET to convert into equity of the borrower if certain events occur. An investment of $2,955,150 buys 4,500 redeemable convertible preferred shares, 4.99%, of Lessengers Inc., the private company POET is already co-developing a 1.6T module with, carried at fair value through other comprehensive income. A company with no product revenue at scale is now also a lender and a minority shareholder in its own development partner.
Burn and runway
Operating cash outflow was $12.2 million in the second quarter of 2026, against $8.8 million in the first quarter and $7.8 million in the second quarter of 2025. For the six months the filed figure is $21,079,966. Annualising the most recent quarter gives roughly $49 million a year, and the cost base is still rising: research and development is up 84% year on year and wages and benefits for the half year run at more than double the prior-year level, with key management compensation alone at $11,160,359 for the six months against $3,751,045.
Against $796.3 million of cash and short-term investments, an operating burn near $49 million a year is not a financing question in any ordinary sense. The company also earns $4.3 million a quarter of interest and other income, which covers a meaningful share of it. POET’s risk is not that it runs out of money before the technology works. It is that money is not what stands between the technology and revenue.
Where the money is meant to go is now itemised in a filing rather than in a presentation. The management discussion sets out a programme table totalling $44 million: $7.0 million on module development through to production in the third quarter of 2027, $6.5 million on light sources for artificial intelligence, $5.5 million on the 800G and 1.6T transmit programme, $7.0 million on the Malaysia expansion through the third quarter of 2026, and $18.0 million on corporate development across 2026. Separately, POET states an approved capital budget of $14.5 million for 2026 covering research and development, equipment, manufacturing equipment and patent registration, of which $5,508,836 was spent in the first half.
That approved capital budget is the number to hold against the roughly $50 million of capital equipment purchases management described at the June annual meeting for the second half of 2026. The two figures are not stated on the same basis and the company does not reconcile them, so what stands is a filed budget of $14.5 million for the year against a $50 million figure stated at a meeting. Capital expenditure is the hardest evidence a capacity expansion is real, and the third quarter cash flow statement is where the answer will be.
Four things to look for in the next interim report, due by November 14, 2026. One: whether any revenue is recognised against the Lumilens order or the October systems-integrator order, and whether the $30,142,069 of deferred customer consideration begins to amortise, which happens only when product revenue from that customer starts. Two: the new $2.4 million purchase order announced on August 13, and whether it ships. Three: property and equipment additions against the $14.5 million approved budget. Four: whether the loan receivable is repaid, converted or extended, and whether the borrower is ever named.
10 Capital structure, warrants and the dilution arithmetic
POET has funded itself entirely with equity, and the share count reflects it. From 76,507,157 shares at January 1, 2025 the company reached 132,021,526 at December 31, 2025, 152,893,604 at March 31, 2026, 172,595,406 at May 18, 2026 173,035,169 at June 30, 2026 and 173,058,088 at August 13, 2026: an increase of 126% in eighteen months. That is the cost of the $830 million of gross proceeds. The second quarter itself added only 439,763 shares, almost all from warrant exercises, because the May offering had already closed before the quarter ended. Share capital on the balance sheet stands at $720,134,275 and the warrant reserve at $435,942,629, against an accumulated deficit of $320,776,480.
Shares in issue against everything exercisable or convertible into shares
- Shares outstanding173.06M66.2%
- Warrants78.73M30.1%
- Options5.37M2.1%
- Restricted stock units4.25M1.6%
Full exercise would lift the count 51% above the 173,058,088 shares in issue at August 13, 2026. Of the warrants, 20,629,268 vest only as Lumilens payment milestones are met and 19,047,620 are struck at $26.25.
Source: Outstanding share data and the options, warrants and RSU note in the management discussion filed August 13, 2026, which states each count at that date.
What is outstanding on top of the shares
| Instrument | Number | Terms | As disclosed at |
|---|---|---|---|
| Common shares | 173,058,088 | No par value, unlimited authorized | August 13, 2026 management discussion |
| Warrants from earlier placements | 36,765,940 | Weighted average exercise price $3.77 at the last disclosed date; 599,001 exercised in the first half of 2026 | December 31, 2025 warrant table, net of first-half exercises |
| May 2026 investor warrant | 19,047,620 | $26.25, three years from May 18, 2026, subject to a 9.99% beneficial ownership blocker | May 18, 2026 closing release and 424B5 |
| Lumilens customer warrant | up to 22,921,408 | $8.25, nine years; 2,292,140 immediately exercisable, the rest vesting against cumulative payments toward $500 million | May 14, 2026 announcement |
| Stock options | 5,369,393 | $1.27 to $6.33, weighted average $2.10 | August 13, 2026 management discussion |
| Restricted stock units | 4,252,504 | Vesting over three years; a further 2,453,271 units were granted to officers on August 11, 2026 and the company does not reconcile that grant with this count | August 13, 2026 management discussion and results release |
| Director RSUs granted after quarter end | 79,450 + 42,920 | Five independent directors in June 2026, plus 21,460 each to the two directors appointed in August 2026 | June 30 and August 3, 2026 releases |
| Convertible debt | $5,800,000 | Carried as a current liability, payable over four years, convertible at the holder’s discretion | June 30, 2026 statements |
The counts stated at August 13, 2026 are 78,734,968 warrants struck between $1.09 and $26.25, 5,369,393 options between $1.27 and $6.33 at a weighted average of $2.10, and 4,252,504 restricted stock units. Adding those to the 173,058,088 shares in issue at the same date gives 261,414,953 on full exercise, 51% above the current count. The warrant table carries a weighted average of $4.39 against the June 30 balance, which cannot be reconciled with tranches of 19,047,620 at $26.25 and 22,921,408 at $8.25: on those two alone the average would have to exceed $9. The tranche-by-tranche figures are used throughout this page in preference to that average. Two qualifications matter. The Lumilens warrant only vests beyond its first tranche if Lumilens actually pays for product, so most of that 22.9 million is a dilution POET would be very happy to suffer. The May investor warrant at $26.25 is well above any price the shares have traded at since May 2026 and does not represent a near-term overhang at anything like current levels.
Management has quantified the upside of the warrant stack, saying at the annual meeting that up to $661 million could be raised if all warrants were exercised. The components can be reconstructed from the warrant table. The May 2026 warrants would bring in $500,000,025 at $26.25. The 36,765,940 warrants left from earlier rounds, carried at a weighted average exercise price of $3.77 at December 31, 2025, would bring in roughly $138.6 million. The 2,292,140 vested Lumilens warrants at $8.25 add $18.9 million. Those three sum to about $657.5 million, close enough to the $661 million cited that the difference sits inside the rounding on the average price. The company does not publish that breakdown, so the arithmetic above is a reconstruction from the disclosed tranches, not a company figure. What management did not say is that the $500 million half of that figure only arrives if the shares trade well above $26.25.
How to read the May 2026 financing. It was non-brokered and sold to a single institutional investor at a premium to the prior close, $21.00 against $20.57. That is unusual and, on its face, a vote of confidence. The market reaction was not: the shares closed at $14.21 on May 18, the day the deal closed, having closed at $20.57 on May 14. Finance advisory fees of $3.25 million in the first quarter of 2026 and $4.63 million in the fourth quarter of 2025 show that “non-brokered” does not mean free.
11 Management and governance
Dr. Suresh Venkatesan has been chief executive since June 2015 and is also chairman. He joined POET from GlobalFoundries, where he was senior vice president of technology development and led the ramp of the 28nm node, and before that held leadership roles at Freescale Semiconductor. He holds a doctorate in electrical engineering from Purdue University and more than 25 U.S. patents. The board and the executive team have both changed materially in 2026.
- Chief financial officer transition under way. Thomas R. Mika, chief financial officer since November 2016, told the board of his intention to retire from the role during 2026 after ten years of service. The announcement was made in the same May 15, 2026 release as the $400 million financing. A search for a successor was described as commencing at that date and no appointment had been announced as of August 9, 2026. Mr. Mika continues to sign the company’s filings, including the August 3, 2026 Form 6-K.
- Chief operating officer appointed. Dr. Sandeep Kumar joined on May 11, 2026 from Silicon Labs, where he was senior vice president of worldwide operations for more than eighteen years, with earlier roles at Agere Systems, Lucent Technologies and AT&T Bell Labs. His remit is the manufacturing scale-up.
- Chief revenue officer. Raju Kankipati is quoted on the commercial announcements, including the October 2025 production order and the Lessengers partnership.
- Board renewal. Jean-Louis Malinge, lead independent director and a director since 2017, resigned effective August 1, 2026 for personal reasons, having been re-elected only five weeks earlier at the June 26 annual meeting. Dr. Bardia Pezeshki and Jean F. Rankin joined the same day. Dr. Pezeshki’s background at Avicena Tech, Kaiam and Santur is directly relevant to optical interconnect. Sohail Khan joined in July 2025 from Coherent Corp.
- Auditor. Davidson & Company LLP was reappointed at the 2026 annual meeting with 97% of votes cast.
The redomiciliation question
The plan was dropped on August 13, 2026. The second quarter results release states that, after careful consideration and with input from the company’s advisors, the board determined that at the present time it is not in the best interests of the company to move forward with redomiciling to the United States. No further explanation is given and no alternative timetable is offered. The consequence is that POET remains a foreign private issuer, keeps reporting on Form 20-F and Form 6-K rather than 10-K, 10-Q and 8-K, stays outside the proxy rules and Section 16 insider reporting, and the passive foreign investment company question stays open rather than being closed by a change of domicile.
The sequence that led there runs as follows. On April 14, 2026 POET said the board had declared its intention to move the company’s headquarters to and redomicile in the United States, so that it would cease to be a foreign corporation and could not be classified as a passive foreign investment company in future years. The chief financial officer said at the time that, to the extent redomiciling required shareholder approval, the matter would be placed on the agenda for the annual general and special meeting scheduled for June 26, 2026. The voting results published on June 30 report two matters: the election of six directors and the appointment of the auditor. No redomiciliation resolution appears in that report. The May 2026 prospectus supplement noted that POET would cease to qualify as a foreign private issuer if and when the relevant conditions occurred. Four months after the announcement of intent, the board reversed it.
PFIC is a tax question, not a footnote. POET confirmed it was a PFIC for the year ended December 31, 2025 and undertook to supply the information needed for a qualified electing fund election, saying that a QEF election for 2025 is not expected to create current income inclusions for holders who continued to hold. It also said it does not expect to qualify as a PFIC for 2026. Anyone holding the shares in a taxable U.S. account should treat this as a matter for a tax adviser, not for a stock report.
12 Ownership, short interest and the retail shareholder base
POET’s register is an unusual shape. Directors and officers as a group held 128,715 shares at March 20, 2026, which on the share count of the time was under one tenth of one percent, and the 20-F table shows individual holdings in the tens of thousands: 33,892 for Malinge, 31,966 for Riley, 31,746 for Barnes, 12,500 for Mika, 11,111 for Kankipati and 7,500 for the chief executive. Finviz reports insider ownership of 0.27%. Management’s economic exposure is therefore overwhelmingly in options and restricted units, not in purchased stock.
The 13G record shows who holds size, and it is worth reading carefully because most of it is not what it first appears to be.
| Holder | Shares | Percent | Event date | Character |
|---|---|---|---|---|
| MMCAP International Inc. SPC / MM Asset Management Inc. | 19,047,620 | 11.0% | May 18, 2026 | The single institutional investor in the $400 million financing. Amendment No. 10 to a long-standing filing; the same manager appears in the 20-F as the only holder above 5% at March 2026. |
| Jane Street Group, LLC | 11,685,828 | 6.8% | June 15, 2026 | Market maker and quantitative trading firm. Shared voting and dispositive power, consistent with trading inventory rather than a directional position. |
| Citadel Securities GP LLC | 10,085,671 | 5.8% | July 8, 2026 | Market maker. Shared voting and dispositive power. |
| Marex Securities Products Inc. / Marex Group plc | 9,150,000 | 6.0% | May 14, 2026 | Broker-dealer position filed the day before the $400 million offering was announced. |
Finviz reports institutional ownership of 73.08%, a figure that should be read with the composition above in mind: a large part of the disclosed institutional total is market-making and dealer inventory, not long-only conviction capital, and there is no index-fund or large active-manager position on the 13G record. Outside those filings, the register is retail. POET has one of the more visible individual-investor followings among small-cap photonics names, with an active community on the AgoraCom message board and heavy daily discussion on social platforms. Retail commentary is non-professional opinion and carries no research standard: it is worth watching as a description of who owns the shares and how quickly they trade, not as evidence about the business.
Short interest is the number that dominates the trading behavior. Finviz reports 30.11% of a float of 90.48 million shares, or roughly 27.2 million shares sold short. At the reported average volume of about 30.85 million shares a day that is well under one day to cover, so this is not a classic hard-to-borrow squeeze setup; it is a very large, very liquid bearish position. It also explains the amplitude of the moves in the price table above: a 47.4% single-session fall on the Marvell cancellation, a 30.9% fall between the announcement and closing of a premium-priced financing, and a 13.45% intraday rise on August 4 on a board appointment.
The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.
Share of sentiment-tagged Stocktwits messages marked bullish, by day. The last column is the most recent reading.
These are self-reported tags from retail traders and non-professional investors, not analyst research. The series measures how crowded one side of the conversation has become, which is a description of the audience rather than of the company.
Source: Stocktwits public sentiment series for $POET, read on August 9, 2026.
Ownership takeaway. Short interest of 30.11% of float and retail sentiment above 96% describe a register crowded in opposite directions. That combination can amplify price moves, but neither the short position nor the bullish message flow is evidence that the commercial ramp will succeed or fail.
13 Catalyst table
| Date or window | Event | Status of the date | Why it matters |
|---|---|---|---|
| September 2026 | Further company announcements on commercial progress | Stated intention in the August 13, 2026 results release. No specific date. | Management tied it to prevailing confidentiality agreements, which points at customer names currently withheld. |
| Remaining quarters of 2026 | Shipment of substantial numbers of production units for qualification | Company statement, August 13, 2026. | Qualification precedes volume revenue. This is the checkpoint that turns the platform into a supply relationship. |
| Second half of 2026 | Shipment of the more-than-$5 million POET Infinity 800G production order | Company target stated October 22, 2025, not reconfirmed in the August 13 release. | Would be the first substantial product revenue in the company’s history. |
| Second half of 2026 | Start of the production ramp at the Malaysian partners | Reaffirmed at the June 26, 2026 annual meeting. | The stated path from roughly $0.5 million a quarter to a materially different revenue base. |
| Q4 2026 | Prototype of the light source for artificial intelligence programme | Milestone table in the August 13, 2026 management discussion, with $2.0 million of expenditure attached. | One of the few dated engineering milestones the company puts in a filing rather than a press release. |
| Q4 2026 | Prototypes of the 800G and 1.6T transmit programme | Milestone table in the August 13, 2026 management discussion, $2.0 million attached. | The transmit side of the roadmap that the order book is written against. |
| Q3 2026 | Completion of the Malaysia expansion spend | Milestone table, $7.0 million budgeted across Q3 2025 to Q3 2026. | Capacity has to exist before a ramp can be delivered. |
| Q3 2026 | Samples of the 1.6T 2xDR4 module with Lessengers | Company website, July 14, 2026. Previously targeted for Q2 2026. | A dated engineering milestone that has already slipped once. POET now also holds 4.99% of Lessengers. |
| Second half of 2026 | Completion of the QCi 400G-per-lane TFLN modulator development | Stated in the November 11, 2025 announcement. | Gates the 3.2T co-packaged optics roadmap. POET is funding it. |
| Late 2026 | Engineering samples from the Lumilens EOI program | Stated in the May 14, 2026 announcement. | The first technical checkpoint on the $50 million order. |
| By Nov 14, 2026 | Third quarter 2026 interim statements and MD&A | Regulatory deadline under NI 51-102, not an announced date. | First print in which qualification shipments, if they happen, could appear in revenue or in deferred balances. |
| During 2026 | Appointment of a new chief financial officer | Search commenced May 2026, no appointment announced as of August 13. | A company holding $796.3 million with a retiring CFO and no named successor. |
| Q1 2027 | Module development prototype stage | Milestone table, $2.0 million attached, within a $7.0 million programme. | Modules are the higher-value product above the engine. |
| 2027 | Production ramp aligned to hyperscaler deployments under the Lumilens program | Company statement, May 14, 2026. | Where the $500 million framework would begin to convert, if it converts. |
| Q2 and Q3 2027 | Production stage on the module, light source and 800G/1.6T programmes | Milestone table in the August 13, 2026 management discussion. | The company’s own dated map of when development stops and production starts. |
| End of 2027 | Capacity of up to one million units per month | Management target stated at the annual meeting, described as more than ten times current capacity. | The scale on which the $500 million framework depends. |
| Withdrawn | U.S. redomiciliation | Board determined on or before August 13, 2026 that it is not in the best interests of the company to proceed at the present time. | POET stays on the 20-F and 6-K regime, and the PFIC question stays open as a matter for a tax adviser. |
Dates in the second column of the milestone rows come from the expenditure table published inside the management discussion of August 13, 2026, which attaches a stage, a target quarter and a dollar figure to each programme. That table carries the company’s own caution that it represents management opinions and estimates and is subject to change.
14 The constructive case and the skeptical case
Constructive
- The bottleneck is real and it is where POET sits. Optical interconnect is the binding constraint on scaling AI clusters, and the industry is moving from 400G to 800G to 1.6T inside a single capital cycle.
- Active alignment is a genuine cost and yield problem in optical module assembly, and a wafer-level platform that removes it is attacking the right thing rather than competing on incremental component performance.
- The counterparty list is not a list of unknowns. LITEON, Semtech, NTT Innovative Devices, Sivers and Quantum Computing Inc. are established companies that have chosen to engineer alongside POET.
- The balance sheet removes the financing risk that usually kills companies at this stage. Roughly $830 million against $5.8 million of convertible debt means POET can fund a ten-fold capacity expansion, a $50 million equipment program and acquisitions without returning to the market.
- The May 2026 financing was sold to a single institutional investor at a premium to the market price, non-brokered, which is a different signal from a discounted marketed deal.
- Manufacturing has been moved out of a Chinese joint venture the company could not control into two Malaysian contract partners, which removes a geopolitical dependency before it became a problem.
- The Optical Interposer is a platform rather than a product: the same substrate architecture is being extended from 800G to 1.6T to a 3.2T roadmap, which is the argument for customers qualifying once.
Skeptical
- Cumulative revenue of $2.09 million since the start of 2023 against an accumulated deficit of $309.4 million. Whatever the technology proves, commercial conversion has not yet happened at any scale.
- The most-cited commercial validation of the platform, the Celestial AI orders, was cancelled in April 2026 by an acquirer, for a stated reason relating to confidentiality rather than product. Concentrated customer relationships can disappear in a letter.
- The $50 million Lumilens order is explicitly conditional on development, qualification and manufacturing scale-up, and the counterparty is a venture-backed private company rather than an established buyer.
- The Lumilens warrant over up to 22,921,408 shares at $8.25 means the largest disclosed order also carries the largest single block of potential customer dilution.
- Share count up 126% in seventeen months. The technology thesis has been correct for years and per-share value has been diluted throughout.
- Costs are climbing faster than revenue: total operating costs rose from $9.0 million in the second quarter of 2025 to $18.4 million in the first quarter of 2026, and $3.25 million of the latest quarter was finance advisory fees.
- Dated milestones have slipped. The Lessengers sample target moved from the second to the third quarter of 2026 without an announcement, in a website note.
- The chief financial officer is retiring with no named successor while the company sits on roughly $830 million, and there is no quarterly conference call at which questions can be asked.
- Short interest of 30.11% of float means a very large body of capital is positioned against the ramp happening on schedule.
15 Scenario framework
These are analytical frameworks for organizing the evidence as it arrives. They are not forecasts, price targets or probabilities, and nothing here should be read as a view on what the shares will do.
| Framework | What would have to be observed | Where it would show up first |
|---|---|---|
| Conversion | Revenue moves from hundreds of thousands per quarter to millions, with shipments recognized against the October 2025 systems-integrator order and then the Lumilens program. Capital expenditure runs at the stated pace. The Malaysian lines qualify. | The revenue line and the property and equipment additions in the interim statements; a customer naming POET in its own disclosure. |
| Platform without volume | The engineering milestones are met and the collaborations multiply, but qualification cycles and customer program timing push volume revenue beyond 2027 while the cost base continues to rise. | Slipping sample and ramp dates; operating costs rising while revenue stays flat; capital expenditure well below the $50 million second-half plan. |
| Order concentration repeat | A single large counterparty again accounts for most of the disclosed commercial pipeline, and that counterparty changes its plans, is acquired, or fails to qualify the module. | Any disclosure about Lumilens; the absence of new named orders; the customer warrant vesting schedule failing to progress past its first tranche. |
| Balance sheet as strategy | The cash is deployed on acquisitions, which management has said is a high priority, changing the company from a single-platform developer into something broader before the platform has generated revenue. | Announcements of targeted acquisitions; a fall in short-term investments not explained by operating burn or capital expenditure. |
16 Merlintrader bottom line
POET leaves its second quarter print as two companies that share a ticker. One is a photonics platform company with a defensible technical argument, a credible partner list and product families that have won industry awards and moved from 800G to a 1.6T and 3.2T roadmap. The other is a business that has recognised $2.66 million of revenue in three and a half years, holds $796.3 million of shareholder money, has issued 126% more shares since the start of 2025 and watched its most-cited customer relationship end in a cancellation letter.
The print itself was clean on its own terms. Revenue grew for the sixth consecutive quarter, the loss narrowed, and the cash figure that management had been quoting from a podium is now a filed number, $796,341,903, sitting inside a balance sheet with $34.3 million of total liabilities of which only $5.8 million is debt. The largest cost of the quarter was not engineering but the $6,172,500 of finance advisory fees paid to raise the money, which is a fair summary of where the company still is: the balance sheet is the achievement, the income statement is the ambition.
The evidence hierarchy is unusually clean here. Revenue on a filed income statement is fact. The Lumilens $50 million, the $5 million systems-integrator order and the new $2.4 million order announced on August 13 are signed but conditional, and the company itself says so. LITEON, Lessengers, Semtech, Sivers, NTT and QCi are development work with no order attached, two of them funded by POET, and one of them, Lessengers, is now also a company POET owns 4.99% of. The “more than $100 million in future annual revenue” from ten engagements is a management expectation. Those four tiers should not be added together, and most commentary about this company adds them together.
Three things changed on August 13 beyond the numbers. The redomiciliation to the United States, announced as a board intention in April, was dropped, which keeps POET on the foreign private issuer regime and leaves the passive foreign investment company question where it was. The company disclosed that it has become a lender, with $30 million advanced to a borrower it does not name, and a shareholder in a development partner. And management put a date on its own next move by saying further announcements will come in September, tied explicitly to confidentiality agreements, which is as close as a filing comes to saying that customer names exist and are not yet public.
What has not changed is the shape of the question. POET no longer has a funding problem and, with $796 million against a $49 million annual operating burn, will not have one for a long time. It has a delivery problem. The company says it will begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026; the third quarter report, due by November 14, is the first document in which that claim becomes checkable against a revenue line, a deferred balance and a capital expenditure figure.
For broader catalyst tracking across the space, defense and AI complex, the Merlintrader Free Catalyst Calendar lists the dated events for the sector.
Related Research On Merlintrader
- Why AI Needs Optics: the optical interconnect stack explained — the framework behind the technology section above, from pluggables to co-packaged optics.
- Three different ways to play the AI photonics race — how $POET compares with larger listed optical component suppliers.
- The Marvell cancellation of the Celestial AI orders — the April 2026 event covered in detail at the time.
- LightPath Technologies ($LPTH) Stock Hub — another small-cap optics manufacturer with a defense and infrared angle.
- Dilution, ATM offerings, PIPE deals and reverse splits: a practical guide — background for the capital structure section.
- Space, Defense & AI Stock Hubs 2026 — the full index of company hubs in this sector.
- Weekly Market Pulse — the week ahead across catalysts and earnings.
Primary Sources And Reference Links
- Form 6-K filed August 13, 2026, with the condensed interim consolidated financial statements and the management discussion and analysis for the six months ended June 30, 2026: the balance sheet, the eight-quarter operating table, working capital, the loan receivable, the Lessengers investment, the deferred customer consideration note, the derivative warrant liability note and the warrant, option and unit counts stated at August 13, 2026.
- Second quarter 2026 results release, August 13, 2026: revenue up 112% year on year, net loss of $0.07 per share, cash and short-term investments of $796.3 million, the three post-quarter business items, the August 11 restricted stock unit grant, the September announcement intention and the decision not to proceed with redomiciling to the United States.
- Form 20-F for the year ended December 31, 2025, filed March 31, 2026: audited statements, segment revenue, capital expenditure, employees, the Super Photonics Xiamen wind-up, the Malaysian manufacturing agreements and the beneficial ownership table.
- Form 6-K of May 15, 2026 with the unaudited condensed interim consolidated financial statements and MD&A for the three months ended March 31, 2026: balance sheet, share capital note, warrant and option tables, contract liabilities.
- First quarter 2026 results release, May 14, 2026: revenue of $503,389, net loss of $12.3 million, operating cash flow of negative $8.8 million and the five-quarter operating summary used for the charts.
- POET and Lumilens announcement, May 14, 2026: the $50 million initial purchase order, the $500 million framework, the 22,921,408-share warrant at $8.25 and the qualification condition.
- Closing of the US$400 million investment, May 18, 2026, and the prospectus supplement filed the same day: 19,047,620 shares and a warrant at $26.25, and the 172,595,406 share count.
- Schedule 13G/A of May 20, 2026 identifying MMCAP International Inc. SPC and MM Asset Management Inc. with 19,047,620 shares and 11.0% of the class, plus the Citadel Securities 13G of July 8, 2026 and the Jane Street 13G of June 22, 2026.
- Purchase Order Update, April 27, 2026: the cancellation by Marvell of all Celestial AI purchase orders, effective on written notice of April 23, 2026.
- 2026 annual meeting recap and voting results, June 30, 2026: the $830 million raised, the $661 million of potential warrant proceeds, the ten-plus customer engagements, the ramp timing, the $50 million equipment plan and the 172,590,000 shares outstanding.
- Board appointments, August 3, 2026: Dr. Bardia Pezeshki and Jean F. Rankin appointed, Jean-Louis Malinge resigned, effective August 1, 2026.
- PFIC status and redomiciliation intention, April 14, 2026, and the TSX Venture Exchange delisting announcement of August 25, 2025.
- Earlier commercial announcements: the $5 million production order for POET Infinity 800G engines (October 22, 2025), the LITEON collaboration (March 16, 2026), the Lessengers 1.6T 2xDR4 partnership (March 17, 2026) and the Quantum Computing Inc. 3.2T collaboration (November 11, 2025).
- POET’s own website: FAQ on production orders, cash position and the path to greater revenue (July 14, 2026, source of the $830 million-plus cash statement, the 30,000-engine 2026 shipment target and the Q3 2026 Lessengers sample date) and the investor relations pages.
- National Instrument 51-102, Part 4: the 45-day interim filing deadline for non-venture issuers, which sets the August 14, 2026 date used above.
Share price, market capitalization, float, short interest, ownership percentages, performance figures and the consensus target price are Finviz Elite data as of August 7, 2026, cross-checked against an independent end-of-day quote provider for the closing prices and the 52-week range. All company financial data, share counts, order values and contract terms come from POET Technologies’ filings on EDGAR and SEDAR+ and from its own press releases. All amounts are in United States dollars, POET’s reporting currency, except where a Canadian dollar amount from an earlier financing is stated as such.
Price and performance data are through the completed August 7, 2026 session; float, short interest, ownership and the consensus target are Finviz fields pulled the same day. All company financial figures come from SEC filings and the company’s own releases, each with its own reference date. Stocktwits data is used only for the clearly labelled retail-sentiment snapshot, read on August 9, 2026.
Get these reports in real time
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $POET or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Space infrastructure, defence technology and applied artificial intelligence companies carry substantial risk. Programme delays, cost overruns, launch failures, contract cancellations and changes in government procurement can move results sharply from one quarter to the next. Contract ceilings and vendor-pool positions are not orders. Companies that fund themselves through at-the-market equity programmes or convertible instruments can dilute existing holders materially and without advance notice, and businesses at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Earnings dates, launch windows, regulatory deadlines and clinical catalysts in one free, filterable calendar.
Open the calendar →



